Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 2/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.37 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4412319 | 0.86 | USP30 (0.43) | USP30TP53SCN9A | |
| SCHEMBL4408961 | 0.86 | USP30 (0.43) | USP30TP53FPR2SCN9A | |
| SCHEMBL4410012 | 0.85 | USP30 (0.42) | USP30TP53HTR2AHTR2CHTR2B | |
| SCHEMBL4415998 | 0.85 | USP30 (0.42) | USP30TP53HTR2AHTR2CHTR2B | |
| SCHEMBL4411286 | 0.84 | USP30 (0.44) | USP30 | |
| SCHEMBL4410015 | 0.83 | SCN9A (0.42) | USP30TP53GPR119SCN9A | |
| SCHEMBL4408213 | 0.82 | USP30 (0.43) | USP30TP53HTR2AHTR2CHTR2B | |
| SCHEMBL4418327 | 0.81 | USP30 (0.40) | USP30TP53SCN9A | |
| SCHEMBL4410458 | 0.81 | USP30 (0.39) | USP30TP53FPR2SCN9A | |
| SCHEMBL4410448 | 0.81 | USP30 (0.39) | USP30TP53FPR2SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318412-A1 | Tricyclic heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318412-A1 | Tricyclic heterocyclic compound and use thereof | HTR2C, HTR2A, HTR5A | USP30 4369/4885TP53 2722/4885HTR2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.